Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

Ret Proto-Oncogene anticorps (AA 29-300)

RET Reactivité: Humain WB, ELISA, IHC Hôte: Lapin Polyclonal unconjugated
N° du produit ABIN7166493
  • Antigène Voir toutes Ret Proto-Oncogene (RET) Anticorps
    Ret Proto-Oncogene (RET)
    Épitope
    • 27
    • 21
    • 15
    • 15
    • 15
    • 11
    • 9
    • 9
    • 8
    • 8
    • 8
    • 7
    • 6
    • 6
    • 4
    • 4
    • 4
    • 3
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    AA 29-300
    Reactivité
    • 162
    • 100
    • 81
    • 5
    • 3
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Humain
    Hôte
    • 185
    • 22
    • 2
    • 1
    • 1
    • 1
    Lapin
    Clonalité
    • 180
    • 32
    Polyclonal
    Conjugué
    • 89
    • 14
    • 10
    • 9
    • 9
    • 9
    • 9
    • 9
    • 9
    • 9
    • 6
    • 5
    • 5
    • 5
    • 5
    • 5
    • 4
    • 1
    Cet anticorp Ret Proto-Oncogene est non-conjugé
    Application
    • 170
    • 81
    • 66
    • 65
    • 42
    • 28
    • 18
    • 16
    • 15
    • 10
    • 4
    • 3
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    Western Blotting (WB), ELISA, Immunohistochemistry (IHC)
     Réactivité croisée
    Humain
    Purification
    Antigen Affinity Purified
    Immunogène
    Recombinant Human Proto-oncogene tyrosine-protein kinase receptor Ret protein (29-300AA)
    Isotype
    IgG
    Top Product
    Discover our top product RET Anticorps primaire
  • Indications d'application
    Recommended dilution: WB:1:500-1:2000, IHC:1:20-1:200,
    Restrictions
    For Research Use only
  • Format
    Liquid
    Buffer
    PBS with 0.02 % sodium azide, 50 % glycerol, pH 7.3.
    Agent conservateur
    Sodium azide
    Précaution d'utilisation
    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Stock
    -20 °C,-80 °C
    Stockage commentaire
    Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
  • Antigène
    Ret Proto-Oncogene (RET)
    Autre désignation
    RET (RET Produits)
    Synonymes
    anticorps c-ret, anticorps cret, anticorps etID315074.13, anticorps ret1, anticorps wu:fd13h01, anticorps X-ret, anticorps ret-A, anticorps xret, anticorps RET, anticorps MTC1, anticorps CDHF12, anticorps CDHR16, anticorps HSCR1, anticorps MEN2A, anticorps MEN2B, anticorps PTC, anticorps RET-ELE1, anticorps RET51, anticorps RET9, anticorps c-Ret, anticorps ret proto-oncogene receptor tyrosine kinase, anticorps ret proto-oncogene S homeolog, anticorps ret proto-oncogene, anticorps ret, anticorps ret.S, anticorps RET, anticorps Ret
    Sujet

    Background: Receptor tyrosine-protein kinase involved in numerous cellular mechanisms including cell proliferation, neuronal navigation, cell migration, and cell differentiation upon binding with glial cell derived neurotrophic factor family ligands. Phosphorylates PTK2/FAK1. Regulates both cell death/survival balance and positional information. Required for the molecular mechanisms orchestration during intestine organogenesis, involved in the development of enteric nervous system and renal organogenesis during embryonic life, and promotes the formation of Peyer\\\'s patch-like structures, a major component of the gut-associated lymphoid tissue. Modulates cell adhesion via its cleavage by caspase in sympathetic neurons and mediates cell migration in an integrin (e.g. ITGB1 and ITGB3)-dependent manner. Involved in the development of the neural crest. Active in the absence of ligand, triggering apoptosis through a mechanism that requires receptor intracellular caspase cleavage. Acts as a dependence receptor, in the presence of the ligand GDNF in somatotrophs (within pituitary), promotes survival and down regulates growth hormone (GH) production, but triggers apoptosis in absence of GDNF. Regulates nociceptor survival and size. Triggers the differentiation of rapidly adapting (RA) mechanoreceptors. Mediator of several diseases such as neuroendocrine cancers, these diseases are characterized by aberrant integrins-regulated cell migration.

    Aliases: C ret antibody, Cadherin family member 12 antibody, Cadherin related family member 16 antibody, CDHF 12 antibody, CDHF12 antibody, CDHR16 antibody, ELKS Fusion gene antibody, HSCR 1 antibody, HSCR1 antibody, Hydroxyaryl protein kinase antibody, MEN2A antibody, MEN2B antibody, MTC 1 antibody, MTC1 antibody, Multiple endocrine neoplasia and medullary thyroid carcinoma 1 antibody, Oncogene RET antibody, Proto oncogene tyrosine protein kinase receptor ret antibody, Proto-oncogene c-Ret antibody, Proto-oncogene tyrosine-protein kinase receptor ret antibody, PTC antibody, RET antibody, RET ELE1 antibody, Ret Proto oncogene antibody, RET transforming sequence antibody, RET_HUMAN antibody, RET51 antibody, RET9 antibody, tyrosine-protein kinase receptor ret antibody

    UniProt
    P07949
    Pathways
    Signalisation RTK, Dopaminergic Neurogenesis, Regulation of Cell Size, Tube Formation
Vous êtes ici: